News Center

TargetMol is excited to announce its participation in the upcoming ASCB 2024. The event will be held from December 14 to December 18, 2024, at the San Diego Convention Center in San Diego, California. TargetMol will be located at booth #605, showcasing its latest advancements in research products and services for the life sciences community.

We’re excited to announce a special giveaway for our U.S. customers! Place an order with TargetMol and receive a free 2025 calendar with your shipment. Hurry—this is a first-come, first-served offer, and quantities are limited. Once they’re gone, they’re gone! Don’t miss your chance to kick off the new year with this exclusive gift. Place your order and get ready to make 2025 a year of new discoveries!

5-Fluorouracil (5-FU) is a uracil analog and inhibitor of DNA synthesis, exhibiting antitumor activity by affecting pyrimidine synthesis through thymidylate synthase inhibition; it induces apoptosis and autophagy.

Join TargetMol at DOT booth #110 to explore our latest offerings and innovations in drug discovery and chemical biology. Visit TargetMol at SFN booth #1012 to discover our cutting-edge products and solutions tailored for neuroscience research.

Trametinib is a highly selective MEK inhibitor that blocks the proliferation of tumor cells by inhibiting the key enzymes MEK1/2 in the RAS-RAF-MEK-ERK signaling pathway. It can also activate autophagy and induce apoptosis, playing a crucial role in the treatment of cancers with BRAF mutations. Trametinib is commonly used in research related to the treatment of unresectable or metastatic melanoma with BRAF V600E or V600K mutations.

TargetMol will be participating in The 83rd Annual Meeting of the Japanese Cancer Association (JCA), which will take place from September 19-21, 2024, in Fukuoka, Japan. This prestigious conference brings together leading researchers, clinicians, and industry professionals to explore the latest advancements in cancer research and treatment. Date: September 19 (thu)-21(sat), 2024 Location: Fukuoka International Congress Center, Marine Messe Fukuoka Hall B (マリンメッセ福岡Ｂ館, 〒812-0031 福岡県福岡市博多区沖浜町2−1) Theme: Cancer Research for Perfect Cure TargetMol Booth: No.1 Conference Link: https://site.convention.co.jp/jca2024/ At this year’s event, TargetMol will showcase our extensive range of cutting-edge small molecules and bioactive compounds that support cancer research, drug discovery, and development.We invite all attendees to visit us at Booth No. 1 to learn more about our offerings and explore potential collaborations.

Necrostatin-1 (Nec-1)(Product No. T1847, CAS 4311-88-0) is a necroptosis inhibitor targeting RIPK1 and also an IDO inhibitor. Necrostatin-1 consists of a benzene ring, an aminothiazole ring, and an amide group. These structural features enable it to specifically bind to RIPK1 and inhibit its activity.

TargetMol will be a Gold Sponsor of the prestigious 2024 Harvard Chinese Life Science Annual Symposium, taking place on September 14, 2024. This annual event brings together leading researchers, industry professionals, and innovators from the global life sciences community, with a focus on advancements in biomedical research, biotechnology, and pharmaceutical sciences.

Bortezomibis a 20S proteasome inhibitor (Ki = 0.6 nM) with antitumor activity, capable of inhibiting NF-κB, disrupting the cell cycle, and inducing apoptosis

LY294002(SF 1101) is a broad-spectrum PI3K inhibitor that inhibits PI3Kα, PI3Kδ, and PI3Kβ (IC50=0.5/0.57/0.97 μM). It is also a DNA-PK inhibitor (IC50=1.4 μM) and a CK2 inhibitor (IC50=98 nM), and it can induce apoptosis and autophagy.